The Controversial Approval of Aduhelm

This chapter explores the FDA's contentious decision to approve Aduhelm, a new Alzheimer's drug priced at $55,000, which aims to address the disease's underlying causes. It highlights the debate surrounding the drug's efficacy, the challenges in proving its effectiveness, and the complex dynamics of regulatory processes amidst skepticism from the scientific community. Personal stories from clinical trial participants bring to light the emotional impact of the drug and the desperate search for effective treatments in the Alzheimer's landscape.